These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33101179)

  • 1. Initial Experience With the Next-Generation Resolute Onyx Zotarolimus-Eluting Stent in Symptomatic Intracranial Atherosclerotic Disease.
    Hassan AE; Mohammaden MH; Rabah RR; Tekle WG
    Front Neurol; 2020; 11():570100. PubMed ID: 33101179
    [No Abstract]   [Full Text] [Related]  

  • 2. Resolute onyx stent more effective than wingspan stent at preventing procedural complications and long-term restenosis.
    Hassan AE; Khalil M; Desai S; Tekle WG
    Interv Neuroradiol; 2023 Dec; 29(6):691-695. PubMed ID: 35635224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of drug-eluting, balloon-expandable resolute onyx coronary stent as a novel treatment strategy for vertebral artery ostial stenosis: Case series.
    Lim J; Baig AA; Aguirre AO; Cappuzzo JM; Vakharia K; Rho K; Waqas M; Monteiro A; Fretz TJ; Levy EI; Siddiqui AH
    Interv Neuroradiol; 2024 Aug; 30(4):443-450. PubMed ID: 36357368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of balloon-mounted stent in the treatment of symptomatic intracranial atherosclerotic disease: a multicenter experience.
    Mohammaden MH; Nogueira RG; Tekle W; Ortega-Gutierrez S; Farooqui M; Zevallos CB; Hanel RA; Cortez GM; Aghaebrahim A; Starke RM; Aref H; Elbassiouny A; Gamea A; Alaraj A; Sadeh M; Grigoryan M; Kuybu O; Haussen DC; Sheth SA; Maud A; Cordina SM; Tanweer O; Kan P; Burkhardt JK; Grandhi R; Siddiq F; Hassan AE
    J Neurointerv Surg; 2022 Aug; 14(8):756-761. PubMed ID: 34349013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thirty-Day Outcomes of Resolute Onyx Stent for Symptomatic Intracranial Stenosis: A Multicenter Propensity Score-Matched Comparison With Stenting Versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial.
    Siddiq F; Nunna RS; Beall JM; Khan I; Khan M; Tekle WG; Ezzeldin M; Tanweer O; Burkhardt JK; Jabbour PM; Tjoumakaris SI; Herial NA; Siddiqui AH; Grandhi R; Martin RL; Qureshi AI; Hassan AE
    Neurosurgery; 2023 Jun; 92(6):1155-1162. PubMed ID: 36700730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The resolute Onyx drug eluting stent for neurointervention: A technical series.
    White TG; Shah KA; Koul P; Link T; Dehdashti AR; Katz JM; Patsalides A; Woo HH
    Interv Neuroradiol; 2024 Feb; 30(1):14-21. PubMed ID: 35379028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 101 30-Day Outcomes of Resolute Onyx Stent for Symptomatic Intracranial Stenosis: A Multicenter Propensity-Score Matched Comparison With SAMMPRIS Trial.
    Siddiq F; Nunna RS; Khan I; Khan M; Beall J; Tekle W; Ezzeldin M; Tanweer O; Burkhardt JK; Jabbour P; Tjoumakaris SI; Herial N; Siddiqui AH; Grandhi R; Qureshi AI; Hassan AO
    Neurosurgery; 2023 Apr; 69(Suppl 1):22. PubMed ID: 36924488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease.
    Fiorella D; Chow MM; Anderson M; Woo H; Rasmussen PA; Masaryk TJ
    Neurosurgery; 2007 Aug; 61(2):236-42; discussion 242-3. PubMed ID: 17762735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial.
    Price MJ; Shlofmitz RA; Spriggs DJ; Haldis TA; Myers P; Popma Almonacid A; Maehara A; Dauler M; Peng Y; Mehran R
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):253-259. PubMed ID: 28940882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medium-term results of undersized angioplasty and stenting for symptomatic high-grade intracranial atherosclerotic stenosis with Enterprise.
    Salik AE; Selcuk HH; Zalov H; Kilinc F; Cirak M; Kara B
    Interv Neuroradiol; 2019 Oct; 25(5):484-490. PubMed ID: 30991867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience.
    Ortega-Gutierrez S; Lopez GV; Edgell RC; Mendez AA; Dandapat S; Roa JA; Zevallos CB; Holcombe AL; Hasan D; Derdeyn CP; Rossen J; Samaniego EA
    Front Neurol; 2019; 10():746. PubMed ID: 31379708
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease: A systematic review and meta-analysis.
    Ye G; Yin X; Yang X; Wang J; Qi P; Lu J; Wang L; Wang D
    J Clin Neurosci; 2019 Jan; 59():112-118. PubMed ID: 30401573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Submaximal angioplasty for symptomatic intracranial atherosclerosis: a prospective Phase I study.
    Dumont TM; Sonig A; Mokin M; Eller JL; Sorkin GC; Snyder KV; Hopkins LN; Levy EI; Siddiqui AH
    J Neurosurg; 2016 Oct; 125(4):964-971. PubMed ID: 26745485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solving the Issue of Restenosis After Stenting of Intracranial Stenoses: Experience with Two Thin-Strut Drug-Eluting Stents (DES)-Taxus Element™ and Resolute Integrity™.
    Kurre W; Aguilar-Pérez M; Fischer S; Arnold G; Schmid E; Bäzner H; Henkes H
    Cardiovasc Intervent Radiol; 2015 Jun; 38(3):583-91. PubMed ID: 25342135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients.
    Feng Z; Duan G; Zhang P; Chen L; Xu Y; Hong B; Zhao W; Liu J; Huang Q
    BMC Neurol; 2015 Oct; 15():187. PubMed ID: 26449986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of drug-eluting stent implantation in patients with symptomatic extra- and intracranial atherosclerotic stenoses.
    Kim J; Ban SP; Kim YD; Kwon OK
    J Cerebrovasc Endovasc Neurosurg; 2020 Dec; 22(4):216-224. PubMed ID: 33050686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stenting for symptomatic intracranial vertebrobasilar artery stenosis: 30-day results in a high-volume stroke center.
    Liu L; Zhao X; Mo D; Ma N; Gao F; Miao Z
    Clin Neurol Neurosurg; 2016 Apr; 143():132-8. PubMed ID: 26943722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stent design lowers angiographic but not clinical adverse events in stenting of symptomatic intracranial stenosis - results of a single center study with 100 consecutive patients.
    Rohde S; Seckinger J; Hähnel S; Ringleb PA; Bendszus M; Hartmann M
    Int J Stroke; 2013 Feb; 8(2):87-94. PubMed ID: 22296983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thirty-Day Outcome of a Multicenter Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China.
    Miao Z; Zhang Y; Shuai J; Jiang C; Zhu Q; Chen K; Liu L; Li B; Shi X; Gao L; Liu Y; Wang F; Li Y; Liu T; Zheng H; Wang Y; Wang Y;
    Stroke; 2015 Oct; 46(10):2822-9. PubMed ID: 26286544
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.